China's drug regulator approved Sailong Pharmaceutical (SHE:002898) subsidiary Hunan Sailong Pharmaceutical's tedizolid phosphate injection, according to a Friday filing with the Shenzhen bourse.
The injection is indicated for acute bacterial skin and soft tissue infections.
Approval is valid until May 18, 2031.